Wappler F, Scholz J, Prause A, Möllenberg O, Bause H, Schulte am Esch J
Abteilung für Anästhesiologie, Universitäts-Krankenhaus Eppendorf, Hamburg.
Anasthesiol Intensivmed Notfallmed Schmerzther. 1998 Jan;33(1):8-26.
The efficacy of a 3-level regimen of analgesia and sedation was investigated in a clinical setting. Level 1 consisted of continuous administration of sufentanil, in level 2 continuous administration of midazolam and level 3 continuous administration of midazolam and clonidine was added according to patients' needs.
Sufentanil at 1 microgram/kg/h was given initially. Later it was adjusted to patients' requirements in accordance with the Ramsay score (group 1). Long-term intubated patients received in addition midazolam 0.05 mg/kg/h (group 2). If needed, clonidine 1 microgram/kg/h was added (group 3). Mean drug requirements were investigated during controlled ventilation and during assisted ventilation with spontaneous breathing > 25% of total minute ventilation. In group 1 arterial paCO2 was measured to estimate drug-induced respiratory depression. Values given are median and ranges.
With the 3-level-regimen of analgesia and sedation a Ramsay score of 2-3 was achieved in all intensive-care patients. In group 1 (n = 109; 36.7%) paCO2 values were similar at all times. Patients on controlled ventilation needed sufentanil 0.6 (0.075-2.5) microgram/kg/h, on assisted ventilation 0.4 (0.05-2.5) microgram/kg/h. Patients of group 2 (n = 113; 38.1%) had on controlled ventilation a higher requirement of sufentanil 1.2 (0.09-2.7) micrograms/kg/h, in addition Midazolam 0.05 (0.002-0.56) mg/kg/h was given. On assisted ventilation with spontaneous breathing > 25% sufentanil 0.9 (0.05-2.6) microgram/kg/h plus midazolam 0.04 (0.002-0.38) mg/kg/h was sufficient. Group 3 (n = 75; 25.2%) had on controlled ventilation a higher requirement of sufentanil with 1.5 (0.09-4.0) micrograms/kg/h and midazolam 0.05 (0.005-0.52) mg/kg/h, in addition clonidine 1.1 (0.12-2.88) micrograms/kg/h was given. On assisted ventilation with spontaneous breathing > 25% requirement of sufentanil with 1.1 (0.15-2.6) micrograms/kg/h and of midazolam with 0.05 (0.002-0.22) mg/kg/h was slightly lower, whereas more clonidine was needed with 1.3 (0.12-2.88) micrograms/kg/h.
Continuous infusion of sufentanil only for analgesia and sedation is suitable for intensive-care patients with a short stay in the ICU. Respiratory depression during spontaneous breathing is not significant. The supplementary administration of midazolam and clonidine according to the presented regimen was shown to be of advantage for patients with a longer stay in ICU.
在临床环境中研究三级镇痛和镇静方案的疗效。一级为持续输注舒芬太尼,二级为持续输注咪达唑仑,三级根据患者需求加用持续输注咪达唑仑和可乐定。
初始给予舒芬太尼1微克/千克/小时,随后根据拉姆齐评分进行调整(第1组)。长期插管患者还接受咪达唑仑0.05毫克/千克/小时(第2组)。如有需要,加用可乐定1微克/千克/小时(第3组)。在控制通气期间以及自主呼吸占总分钟通气量>25%的辅助通气期间,研究平均药物需求量。在第1组中测量动脉血二氧化碳分压以评估药物引起的呼吸抑制。给出的值为中位数和范围。
采用三级镇痛和镇静方案,所有重症监护患者的拉姆齐评分为2 - 3分。第1组(n = 109;36.7%)的动脉血二氧化碳分压值在所有时间均相似。控制通气的患者需要舒芬太尼0.6(0.075 - 2.5)微克/千克/小时,辅助通气时需要0.4(0.05 - 2.5)微克/千克/小时。第2组(n = 113;38.1%)的患者在控制通气时对舒芬太尼的需求量更高,为1.2(0.09 - 2.7)微克/千克/小时,此外还给予咪达唑仑0.05(0.002 - 0.56)毫克/千克/小时。自主呼吸>25%的辅助通气时,舒芬太尼0.9(0.05 - 2.6)微克/千克/小时加咪达唑仑0.04(0.002 - 0.38)毫克/千克/小时就足够了。第3组(n = 75;25.2%)的患者在控制通气时对舒芬太尼的需求量更高,为1.5(0.09 - 4.0)微克/千克/小时,咪达唑仑0.05(0.005 - 0.52)毫克/千克/小时,此外还给予可乐定1.1(0.12 - 2.88)微克/千克/小时。自主呼吸>25%的辅助通气时,舒芬太尼1.1(0.15 - 2.6)微克/千克/小时和咪达唑仑0.05(0.002 - 0.22)毫克/千克/小时的需求量略低,而可乐定需要量更多,为1.3(0.12 - 2.88)微克/千克/小时。
仅持续输注舒芬太尼用于镇痛和镇静适用于在重症监护病房停留时间较短的重症监护患者。自主呼吸期间的呼吸抑制不明显。根据所提出的方案补充给予咪达唑仑和可乐定对在重症监护病房停留时间较长的患者有优势。